Respiration Disorders
AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks
AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases
GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines
GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership